Alkermes (ALKS) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +16.67%. A quarter ago, it was expected that this drugmaker would post earnings of $0.41 per share when it actually produced earnings of $0.52, delivering a surprise of +26.83%.Over the last four quarters, the company has ...

Financial Performance - Net income from continuing operations for Q3 2025 was $82.8 million, down from $92.8 million in Q3 2024, representing a decrease of 10.8%[87] - Total revenues for Q3 2025 increased by $16.0 million compared to Q3 2024, primarily driven by an increase in product sales, net[88] - For the nine months ended September 30, 2025, net income from continuing operations decreased by $34.1 million, attributed to a $36.3 million decline in revenues, mainly from lower manufacturing and royalty revenues[89] - For the three months ended September 30, 2025, product sales, net, increased to $317.4 million, a 16.2% increase from $273.0 million in the same period of 2024[113] - The gross product sales for the nine months ended September 30, 2025, reached $1,631.1 million, compared to $1,543.8 million in 2024, reflecting a 5.7% increase[113] Product Sales and Revenue - LYBALVI units sold increased by 19% during the nine months ended September 30, 2025, contributing significantly to the overall sales growth[114] - Medicaid rebates decreased by approximately $7.6 million for VIVITROL and $4.9 million for ARISTADA/ARISTADA INITIO during the three months ended September 30, 2025, compared to the same period in 2024[115] - Manufacturing and royalty revenues for the three months ended September 30, 2025, were $76.8 million, down from $105.1 million in 2024, a decrease of 27%[117] - The increase in RISPERDAL CONSTA revenue during the nine months ended September 30, 2025, was due to an $8.2 million increase in manufacturing revenue[118] - The company expects continued lower royalty revenues from long-acting INVEGA products due to the expiration of royalties on net sales in August 2024[117] Research and Development - The company is focused on R&D for innovative medicines in neuroscience, with significant resources allocated to preclinical work and clinical studies[111] - Research and development expenses include both external and internal costs, with external expenses tracked for each development program[121] - The company plans to initiate a phase 3 program in narcolepsy following the completion of phase 2 studies, including the Vibrance-1 study results announced in September 2025[112] - Total external R&D expenses increased by 66.2% to $43.2 million for the three months ended September 30, 2025, compared to $26.0 million in the same period of 2024[122] - Alixorexton development expenses rose to $25.8 million for the three months ended September 30, 2025, up from $11.9 million in 2024, reflecting increased spending on clinical studies[123] - Internal R&D expenses increased by 11.6% to $38.5 million for the three months ended September 30, 2025, compared to $33.8 million in 2024[125] Expenses and Cash Flow - Selling and marketing expenses rose by 14.0% to $115.6 million for the three months ended September 30, 2025, compared to $102.1 million in 2024[125] - General and administrative expenses increased by 16.5% to $56.2 million for the three months ended September 30, 2025, compared to $48.2 million in 2024[126] - Cash and cash equivalents totaled $616.4 million as of September 30, 2025, up from $291.1 million at the beginning of the period[130] - Cash generated from operating activities was $350.6 million for the nine months ended September 30, 2025, compared to $248.7 million in 2024[131] - Operating cash flow for the nine months ended September 30, 2025, was $192.3 million, down from $220.6 million in the same period of 2024, reflecting a decrease of approximately 12%[138][139] Acquisition and Financing - The company announced a proposed acquisition of Avadel for up to $20.00 per share, expected to complete in Q1 2026, with anticipated costs of $15.0 million to $20.0 million related to the acquisition[91] - The company entered into a Bridge Credit Agreement for up to $1.2 billion to finance a proposed acquisition, with $700 million placed in escrow for this purpose[134] Shareholder Returns and Investments - Share-based compensation for the nine months ended September 30, 2025, was $72.4 million, compared to $75.9 million in 2024, indicating a decrease of about 4.6%[138][139] - Cash flows used in investing activities for the nine months ended September 30, 2025, included $40.4 million for property, plant, and equipment purchases, significantly lower than $23.7 million in 2024[140] - Cash flows provided by financing activities for the nine months ended September 30, 2025, included $32.2 million from employee stock option exercises, compared to $19.4 million in 2024, representing a 65% increase[141] - The company reported changes in working capital of $27.7 million for the nine months ended September 30, 2025, compared to a negative change of $105.1 million in 2024[138][139] - The company repurchased $200.0 million of ordinary shares under the Repurchase Program during the nine months ended September 30, 2024[141] Market Risk and Currency Exposure - The company has not anticipated any near-term changes in market risk exposures since December 31, 2024, indicating stability in its investment strategy[145][146] - Non-U.S. currency exchange risk primarily relates to royalty revenues, with no material change in sensitivity assessment since December 31, 2024[146] - The company continues to focus on preserving capital and generating investment income through regular reviews of its marketable securities holdings[145]

Alkermes (NasdaqGS:ALKS) Q3 2025 Earnings Call October 28, 2025 08:00 AM ET Company ParticipantsTodd Nichols - Chief Commercial OfficerRichard Pops - CEOChi Eze - Perfomance ManagerJoshua Reid - CFOPaul Matisse - Managing DirectorDouglas Tsao - Managing Director of Equity ResearchLeonid Timoshev - Head of Healthcare ResearchManoj Radder - VPAmi Fadia - Stock analystSandra Coombs - SVP, Investor Relations and Corporate AffairsConference Call ParticipantsNone - AnalystNone - AnalystNone - AnalystJoseph Thome ...

Alkermes (NasdaqGS:ALKS) Q3 2025 Earnings Call October 28, 2025 08:00 AM ET Speaker6Greetings. Welcome to the Alkermes third quarter 2025 financial results conference call. My name is Rob, and I'll be your operator for today's call. All participant lines will be placed on mute to prevent background noise. If you should require operator assistance during the call, please press star zero from your telephone keypad. Please note that this conference is being recorded. I will now turn the call over to Sandra Coo ...

Third Quarter 2025 Financial Results & Business Update October 28, 2025 Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkermes plc's (the "Company") expectations with respect to its current and future financial, commercial and operating performance, business plans ...

Accessibility StatementSkip Navigation —Â Â Â Third Quarter Revenues of $394.2 Million — —Â Â Â GAAP Net Income of $82.8 Million and Diluted GAAP Earnings per Share of $0.49 — —Â Â Â Company Raises 2025 Financial Expectations — Revenues | (In millions) | Three Months Ended | Nine Months Ended | | | | | --- | --- | --- | --- | --- | --- | | | September 30, | September 30, | | | | | 2025 | 2024 | 2025 | 2024 | | | | Total Revenues | $ | 394.2 | $ | 378.1 $ 1,091.4 $ 1,127.6 | | | Total Proprietary Net Sales | ...

Group 1 - Avadel Pharmaceuticals (AVDL) has accepted a buyout offer from Alkermes plc (ALKS) following the settlement of litigation with Jazz Pharmaceuticals (JAZZ) [1] - This acquisition is part of a series of notable acquisitions in the biotech sector [1] Group 2 - The Biotech Forum, led by Bret, offers a model portfolio of 12-20 high upside biotech stocks, along with live chat discussions and weekly research updates [1]

Key Takeaways Alkermes will acquire Avadel for up to $20 per share in a cash deal valued at $2.1 billion.The acquisition will grant Alkermes access to Lumryz, a fast-growing therapy for narcolepsy.The deal supports Alkermes' orexin program and entry into the high-growth sleep medicine market.Alkermes plc (ALKS) announced that it has entered into a definitive agreement to acquire Ireland-based Avadel Pharmaceuticals (AVDL) in a deal valued at up to $20.00 per share in cash, representing a total transaction v ...

Alkermes has agreed to acquire Avadel Pharmaceuticals for up to $20 per share in cash, valuing Avadel at $2.1bn. The acquisition expedites the entry of Alkermes into the sleep medicine sector. The transaction received approval from the board of directors of both companies and will conclude in the first quarter of 2026. It will add Avadel’s US Food and Drug Administration (FDA)-approved therapy, Lumryz (sodium oxybate), to Alkermes’ commercial portfolio. The therapy is used to treat cataplexy or excessi ...

Core Viewpoint - Alkermes plc is making a strategic acquisition of Avadel Pharmaceuticals valued at up to $2.1 billion to enhance its position in the sleep medicine market, particularly focusing on central nervous system disorders [2][5]. Group 1: Acquisition Details - The acquisition will leverage Avadel's drug Lumryz, which treats excessive daytime sleepiness in narcolepsy patients, and aims to unlock the potential of Alkermes' late-stage pipeline [2]. - The deal values Avadel's stock at $18.50 per share, with an additional contingent value right (CVR) of $1.50 per share, contingent on FDA approval of Lumryz for idiopathic hypersomnia by the end of 2028 [3][5]. Group 2: Financial Aspects - Alkermes plans to finance the acquisition using its cash reserves and by issuing new debt [3][5]. - At the time of the acquisition announcement, Alkermes' stock price was $31.84, and it experienced a decline following the news, while Avadel's shares increased [3]. Group 3: Stock Performance - On the trading day of the announcement, Alkermes' stock was priced at $31.74, reflecting a 0.93% increase with a trading volume of 2,154,100 shares [4]. - Over the past year, Alkermes' stock has fluctuated between a high of $36.45 and a low of $25.17, with a current market capitalization of approximately $5.24 billion [4].